Potential effects of flavonoids on the etiology of vascular disease

Journal of Nutritional Biochemistry

Volumn 9, Issue 10, 1998, Pages 560-566

  Schramm, Derek D ^a   German, J Bruce ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AGE; Atherosclerosis; Estrogen; Flavonoids; Immune system; Vascular disease

Indexed keywords

CARBOHYDRATE; ESTROGEN; FLAVONOID; PROTEINASE; RECEPTOR;

ATHEROSCLEROSIS; ESTROGEN ACTIVITY; HUMAN; IMMUNE SYSTEM; REVIEW; VASCULAR DISEASE; VIRUS REPLICATION;

EID: 0032188899     PISSN: 09552863     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0955-2863(98)00051-5     Document Type: Review

References (89)

1. Hertog M.G., Feskins E.J., Hollman P.C., Katan M.B., Kremhout D. Dietary antioxidant flavonoids and risk of coronary heart disease the Zutphen Elderly Study . Lancet. 342:1993;1007-1011.
2. Ruping, X., Wallace, H., Irving, D., Rein, D., Walzem, R.L., and German, J.B. (in press). Effect of dietary catechin and vitamin E on aortic lipid accumulation in hypercholesterolemic hamsters. Atherosclerosis.
3. Blank M.A., Ems B.L., Weisshaar P.S., Ares J.J., Abel P.W., et al. Flavonoid-induced gastroprotection in rats role of blood flow and leukocyte adherence . Digestion. 58:1997;147-154.
4. Rajendran S., Deepalakshmi P.D., Parasakthy K., Devaaraj H., Devaraj S.N. Effect of tincture of carataegus on the LDL-receptor activity of hepatic plasma membrane of rats fed an atherogenic diet. Atherosclerosis. 123:1997;235-241.
5. 2 release is stimulated by wine in vitro one mechanism that may mediate the vasoprotective effects of wine . J. Nutr. Biochem. 8:1997;647-651.
6. Samman S., Lyons Wall P.M., Cook N.C. Flavonoids and coronary heart disease Dietary perspectives . Rice-Evans C.A., Packer L. Flavonoids in Health and Disease. 1998;469-482 Marcel Dekker, New York, USA.
7. Hillis G.S., MacLeod A.M. Integrins and disease. Clin. Sci. 91:1996;639-650.
8. Sluiter W., Pietersma A., Lamers J.M.J., Koster J.F. Leukocyte adhesion molecules on the vascular endothelium their role in the pathogenesis of cardiovascular disease and the mechanisms underlying their expression . J. Cardiol. Pharmacol. 22:(suppl 4):1993;537-544.
9. Butcher E.C. Leukocyte-endothelial cell recognition three (or more) steps to specificity and diversity . Cell. 67:1991;1033-1036.
10. Gerritsen M.E., Carley W.W., Ranges G.E., Shen C.P., Phan S.A., et al. Flavonoids inhibit cytokine-induced endothelial cell adhesion protein gene expression. Am. J. Pathol. 147:1997;278-292.
11. Kimura Y., Matsushita N., Okuda H. Effects of baicalein isolated from Scutellaria baicalensis on interleukin-1 beta- and tumor necrosis factor alpha-induced adhesion molecule expression in cultured human umbilical vein endothelial cells. J. Ethnopharmacol. 57:1997;63-67.
12. Panes J., Gerritsen M.E., Anderson D.C., Miyasaka M., Granger D.N. Apigenin inhibits tumor necrosis factor-induced intercellular adhesion molecule-1 upregulation in vivo. Microcirculation. 3:1996;279-286.
13. Tiisala S., Majuri M.-L., Carpen O., Renkonen R. Genistein enhances the ICAM-mediated adhesion by inducing the expression of ICAM-1 and its counter-receptors. Biochem. Biophys. Res. Commun. 203:1994;443-449.
14. Middleton E. Jr, Kandaswami C. Effects of flavonoids on immune and inflammatory cell functions. Biochem. Pharmcol. 43:1992;1167-1179.
15. Scheld W.M., Zak O., Vosbeck K., Sande M.A. Bacterial adhesion in the pathogenesis of infective endocarditis. J. Clin. Invest. 68:1981;1381-1384.
16. Kurpiewski G.E., Forrester L.J., Campbell B.J., Barrett J.T. Platelet aggregation by Streptococcus pyogenes. Infect. Immun. 39:1983;704-708.
17. Brook I. Brain abscess in children microbiology and management . J. Child Neurol. 10:1995;283-288.
18. Finch R. Chemoprophylaxis of infective endocarditis. Scand. J. Infect. Dis. 70:(suppl):1990;102-110.
19. Spodick D.H. Inflammation and the onset of acute myocardial infarction. Ann. Intern. Med. 102:1992;699-702.
20. Ellis R.W. Infection and coronary heart disease. J. Med. Microbiol. 46:1997;535-539.
21. Bouvet A. Human endocaritis is due to nutritionally variant streptococci Streptococcus adjacens and Streptococcus defectivus . Eur. Heart J. 16:(suppl B):1995;24-27.
22. Mattila K.J. Dental infections as a risk factor for acute myocardial infarction. Eur. Heart J. 14:(suppl K):1993;51-53.
23. Shaw J.H. Causes and control of dental caries. N. Engl. J. Med. 322:1990;996-1004.
24. Rolfe B.G. Flavones and isoflavones as inducing substances of legume nodulation. Biofactors. 1:1988;3-10.
25. Mitrokotsa D., Mitaku S., Demetzos C., Harvala C., Mentis A., et al. Bioactive compounds from the buds of Platanus orientalis and isolation of a new kaempferol glycoside. Planta Med. 59:1993;517-520.
26. Ivancheva S., Manolva N., Serkedjieva J., Dimov V., Ivanovska N. Polyphenols from Bulgarian medicinal plants with anti-infectious activity. Basic Life Sci. 59:1992;717-728.
27. Yamaguci N., Kohno H., Tawara M., Odashima S., Abe H. Effect of saikosaponin derivatives upon the immune response against T-dependent and T-independent antigens in mice. Int. J. Immunopharmacol. 7:1985;827-832.
28. Chung C.P., Park J.B., Bae K.H. Pharmacological effects of methanolic extract from the root of Scutellaria baicalensis and its flavonoids on human gingival fibroblast. Planta Med. 61:1995;150-153.
29. Rueff J., Laires A., Borba H., Chaveca T., Gomes M.I., Halpern M. Genetic toxicology of flavonoids the role of metabolic conditions in the induction of reverse mutation, SOS functions and sister-chromatid exchanges . Mutagenesis. 1:1986;179-183.
30. Schramm, D.D., and J.B. German (1998, March). Decreased endothelial cell-derived endothelin in media containing catechin, wine, or wine components of low or high mass. Keystone Endothelium Symposia, Lake Tahoe, Nevada (Abstract).
31. Yamamoto S., Yamamoto T., Shimada S., Kuramoto E., Yano O., et al. DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells, and inhibits tumor growth. Microbiol. Immunol. 36:1992;983-997.
32. Monier V.M., Sell D.R., Nagaraj R.H., Miyata S., Grandhee S., et al. Maillard reaction-mediated molecular damage to extracellular matrix and other tissue proteins in diabetes, aging, and uremia. Diabetes. 4:1992;36-41.
33. Wells-Knecht K.J., Zyzak D.V., Linchfield J.E., Thrope S.R., Baynes J.W. Mechanism of autoxidative glycosylation identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose . Biochemistry. 34:1995;15134-15141.
34. Lyons T.J. Glycation and oxidation a role in the pathogenesis of atherosclerosis . Am. J. Cardiol. 71:1993;26B-31B.
35. Lee A.T., Cerami A. Role of glycation in aging. Ann. N.Y. Acad. Sci. 663:1992;63-70.
36. Schmidt A.M., Hori O., Brett J., Yan S.D., Wautier J.L., Stern D. Cellular receptors for advanced glycation end products. Arteroscler. Thromb. 14:1994;1521-1528.
37. Schmidt A.M., Hori O., Cao R., Yan S.D., Bret J., et al. RAGE a novel cellular receptor for advanced glycation end products . Diabetes. 45:1996;S77-S80.
38. Yan S.D., Stern D., Schmidt A.M. What's the RAGE? The receptor for advanced glycation end products (RAGE) and the dark side of glucose. Eur. J. Clin. Invest. 27:1997;179-181.
39. Schmidt A.M., Hori O., Chen J.X., Li J.F., Crandall J., et al. Advanced glycation end products interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice a potential mechanism for the accelerated vasculopathy of diabetes . J. Clin. Invest. 96:1995;1395-1403.
40. Fu M.X., Knecht K.J., Thorpe S.R., Baynes J.W. Role of oxygen in crosslinking and chemical modification of collagen by glucose. Diabetes. 41:(suppl 2):1992;42-48.
41. Fu M.X., Wells-Knecht K.J., Blackledge J.A., Lyons T.J., Thorpe S.R., Bynes J.W. Glycation, glycoxidation, and inhibition of late stages of the Maillard reaction. Diabetes. 43:1994;676-683.
42. Schramm, D.D., Bruckner, G., and Boissonneault, G.A. (1996). Flavonoids inhibit hyperglycemia-induced collagen-linked fluorescent-adduct formation. FASEB J. 10 (Abstract: A461).
43. Schramm, D.D. (1996). Flavonoids and flavonoid metabolites inhibit monosaccharide-induced protein damage of the advanced glycation end product (AGE) type. UMI Dissertation Services, MI., UMI # 9709198.
44. Schramm, D.D., Bruckner, G., and Boissonneault, G.A. (1995). Phenolic metabolites of the flavonoid rutin inhibit glycation and oxidation. FASEB J. 9 (Abstract: A153).
45. Baynes J.W., Wells-Knecht K.J., Zyzak D.V., Litchfield J.E., Thrope S.R. Mechanism of autoxidative glycosylation identification of glyoxal and arabinose as intermediates in the autooxidative modification of proteins by glucose . Biochemistry. 34:1995;3702-3709.
46. Odetti P., Borgoglio A., De Pascale A., Rolandi R., Adezati L. Prevention of diabetes-increased aging effect on rat collagen-linked fluorescence by aminoguanidine and rutin. Diabetes. 39:1990;796-800.
47. Master A.M., Dack S., Jafee H.L. Age, sex, and hypertension in myocardial infarction due to coronary occlusion. Arch. Intern. Med. 64:1939;767-786.
48. Kannel W.B., Hjortland M.C., McNamara P.M., Gordon T. Menopause and risk of cardiovascular disease the Framingham Study . Ann. Intern. Med. 85:1976;447-452.
49. Nathan L., Chaudhuri G. Estrogens and atherosclerosis. Annu. Rev. Pharmacol. Toxicol. 37:1997;477-515.
50. Farhat M.Y., Lavigne M.C., Ramwell P.W. The vascular protective effects of estrogen. FASEB J. 10:1996;615-624.
51. Hamm T.E., Kaplan J.R., Clarkson T., Ullock B.C. Effects of gender and social behavior on the development of coronary artery atherosclerosis in cynomolgus macaques. Atherosclerosis. 48:1983;221-233.
52. Stampfer M.J., Colditz G.A. Estrogen replacement therapy and coronary heart disease a quantitative assessment of the epidemiologic evidence . Prev. Med. 20:1991;47-63.
53. Rice-Evans C.A., Packer L. Flavonoids in Health and Disease. 1998;Marcel Dekker, New York, USA.
54. Miksicek R.J. Commonly occurring plant flavonoids have estrogenic activity. Molec. Pharmacol. 44:1993;37-43.
55. Scambia G., Ranelletti F., Panici P.B., Piantelli M., Rumi C., et al. Type-II estrogen binding sites in a lymphoblastoid cell line and growth-inhibitory effect of estrogen, anti-estrogen and bioflavonoids. Int. J. Cancer. 46:1990;1112-1116.
56. Nikkari S.T., O'Brien K.D., Ferguson M., Hatsukami T., Welgus H.G., et al. Interstitial collagenase (MMP-1) expression in human corotid atherosclerosis. Circulation. 92:1995;1393-1398.
57. Simpson R., Kobzik L., Valeri C.R., Shepro D., Hechtman H.B. Neutrophil and nonneutrophil-mediated injury in intestinal ischemia-reperfusion. Ann. Surg. 218:1993;444-454.
58. Sashida H., Abiko Y. Inhibition with NCO-700, a protease inhibitor, of degradation of cardiac myofibrillar proteins during ischaemia in dogs. Biochem. Pharmacol. 34:1985;3875-3880.
59. Barry W.H. Mechanisms of myocardial cell injury during ischaemia and reprofusion. J. Card. Surg. 2:1987;375-383.
60. Hong S.C., Lanzino G., Goto Y., Kang S.K., Schottler F., et al. Calcium-activated proteolysis in rat neocortex induced by transient focal ischaemia. Brain Res. 661:1994;43-50.
61. Mohacsi A., Fulop T., Kozlovsky B., Huack M., Kiss I., Leovey A. Sera and leukocyte elastase-type protease and antiprotease activity in healthy and atherosclerotic subjects of various ages. J. Gerontol. 47:1992;B154-B158.
62. Chapman H.A., Riese R.J., Shi G.P. Emerging roles for cysteine proteses in human biology. Annu. Rev. Physiol. 59:1997;63-88.
63. Lehnert B., Wadouh F., Dwenger A. Relationship between proteolytic enzymes and atherosclerosis in aortic aneurysms. Surgery. 172:1991;345-350.
64. Drubaix I., Viljanen-Tarifa E., Robert A.M., Robert L. Role of glycosaminoglycans in venous disease mode of action of some flavonoid drugs . Pathol. Biol. 43:1994;461-470.
65. Jonadet M., Meunier M.T., Villie F., Bastide J.P., Lamaison J.L. Flavonoids extracted from Ribes nigrum L. and Alchemilla vulgaris L. 1. In vitro inhibitory activity on elastase, trypsin and chymotrypsin: 2. Angioprotective activities compared in vivo . J. Pharmacol. 17:1986;21-27.
66. Robert A.M., Godeau G., Moati F., Miskulin M. Action of anthocanosides of Vaccinium myrtillis on the permeability of the blood brain barrier. J. Med. 8:(5):1977;321-332.
67. Brache M., Vyncke B., Opdenakker G., Foidart J.M., De Pestel G., Mareel M. Effect of catechins and citrus flavonoids on invasion in vitro. Clin. Exp. Metastasis. 9:(1):1991;13-25.
68. Brinkworth R.I., Stoermer M.J., Fairlie D.P. Flavones are inhibitors of HIV-1 proteinase. Biochem. Biophys. Res. Commun. 188:1992;631-637.
69. Tanner G.J., Moore A.E., Larkin P.J. Proanthocyanidins inhibit hydrolysis of leaf proteins by rumen microflora in vitro. Br. J. Nutr. 71:1994;947-958.
70. Caforio A.P., McKenna W.J. Recognition and optimum management of myocarditis. Drugs. 52:1996;515-525.
71. Huber S.A. Autoimmunity in myocarditis relevance of animal models . Clin. Immunol. Immunopathol. 83:1997;93-102.
72. Penninger P.L.J., Aitken K., Sole M., Mak T. The role of transgenic knockout models in defining the pathogenesis of viral heart disease. Eur. Heart J. 16:(suppl O):1995;25-27.
73. Leslie K., Blay R., Haisch C., Lodge A., Weller A., Huber S. Clinical and experimental aspects of viral myocarditis. Clin. Microbiol. Rev. 2:1989;191-203.
74. Betts R.F., Hanshaw J.B. Cytomegalovirus (CMV) in the compromised host(s). Annu. Rev. Med. 28:1977;103-110.
75. Matsumori A., Sasayama S. Newer aspects of pahtogenesis of heart failure hepatitis C virus infection in myocarditis and cardiomyopathy . J. Card. Fail. 2:1996;S187-S194.
76. Ni J., Bowles N.E., Kim Y.H., Demmler G., Kearney D., et al. Viral infection of the myocardium in endocardial fibroelastosis molecular evidence for the role of mumps virus as an etiologic agent . Circulation. 95:1997;133-139.
77. Melnick J.L., Adam E., Debakey M.E. Cytomegalovirus and atherosclerosis. Eur. Heart J. 14:(suppl K):1993;30-38.
78. Formica J.V., Regelson W. Review of the biology of quercetin and related flavonoids. Food Chem. Toxicol. 33:1995;1061-1080.
79. Barnard D.L., Smee D.F., Huffman J.H., Meyerson L.R., Sidwell R.W. Antiherpesvirus activity and mode of action of SP-303, a novel plant flavonoid. Chemotherapy. 39:1993;203-211.
80. Wacker A., Eilmes H.G. Antiviral activity of plant components. Arzneimittelforschung Drug Res. 28:1978;347-350.
81. Sidwell R.W., Huffman J.H., Moscon B.J., Warren R.P. Influenza virus-inhibitory effects of intraperitoneally and aerosol-administered SP-303, a plant flavonoid. Chemotherapy. 40:1994;42-50.
82. Nagai T., Miyaich Y., Tomimori T., Suzuki Y., Yamada H. In vivo anti-influenza virus activity of plant flavonoids possessing inhibitory activity for influenza virus sialidase. Antiviral Res. 19:1992;207-217.
83. Nagai T., Miyaichi Y., Tomimori T., Suzuki Y., Yamada H. Inhibition of influenza virus sialidase and anti-influenza virus activity by plant flavonoids. Chem. Pharm. Bull. 38:1990;1329-1332.
84. Schramm D.D., Donovan J.L., Kelly P.A., Waterhouse A.L., German J.B. Differential effects of small and large molecular weight wine phytochemicals on endothelial cell eicosanoid release. J. Agric. Food Chem. 46:1998;1901-1905.
85. Vecknenstedt A., Pusztai R. Mechanism of antiviral action of quercetin against cardiovirus infection in mice. Antiviral Res. 1:1981;249-261.
86. Critchfield J.W., Butera S.T., Folks T.M. Inhibition of HIV activation in latently infected cells by flavonoid compounds. Aids Res. Hum. Retroviruses. 12:1996;39-46.
87. Saito Y., Okamoto H., Mizusaki S., Daisuke Y. Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced induction of E&B virus early antigen in raji cells by some inhibitors of tumor promotion. Cancer Lett. 32:1986;137-144.
88. Wleklik M., Zahorska R., Luczak M. Interferon-inducing activity of flavonoids. Acta Microbiol. Pol. 36:1987;151-154.
89. Paganga G., Rice-Evans C.A. The identification of flavonoids as glycosides in human plasma. FEBS Lett. 401:1997;78-82.